Limbrick David D, Castaneyra-Ruiz Leandro, Han Roland H, Berger Daniel, McAllister James P, Morales Diego M
Division of Pediatric Neurosurgery, Department of Neurological Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Pediatr Neurosurg. 2017;52(6):426-435. doi: 10.1159/000477175. Epub 2017 Aug 11.
Hydrocephalus (HC) is a common, debilitating neurological condition that requires urgent clinical decision-making. At present, neurosurgeons rely heavily on a patient's history, physical examination findings, neuroimaging, and clinical judgment to make the diagnosis of HC or treatment failure (e.g., shunt malfunction). Unfortunately, these tools, even in combination, do not eliminate subjectivity in clinical decisions. In order to improve the management of infants and children with HC, there is an urgent need for new biomarkers to complement currently available tools and enable clinicians to confidently establish the diagnosis of HC, assess therapeutic efficacy/treatment failure, and evaluate current and future developmental challenges, so that every child has access to the resources they need to optimize their outcome and quality of life.
脑积水（HC）是一种常见的、使人衰弱的神经系统疾病，需要紧急进行临床决策。目前，神经外科医生在很大程度上依赖患者的病史、体格检查结果、神经影像学检查以及临床判断来诊断脑积水或治疗失败（例如分流器故障）。不幸的是，即使将这些工具结合使用，也无法消除临床决策中的主观性。为了改善对脑积水患儿的管理，迫切需要新的生物标志物来补充现有的工具，使临床医生能够自信地诊断脑积水、评估治疗效果/治疗失败情况，并评估当前和未来的发育挑战，以便每个孩子都能获得优化其治疗结果和生活质量所需的资源。
